The present disclosure pertains to medical devices and systems, and methods for manufacturing and using medical devices and systems. More particularly, the present disclosure pertains to medical implants for occluding a left atrial appendage and anchoring tip designs for said medical implants.
Diseases and/or medical conditions that impact the cardiovascular system are prevalent throughout the world. Traditionally, treatment of the cardiovascular system was often conducted by directly accessing the impacted part of the system. More recently, less invasive therapies have been developed, and have gained wide acceptance among patients and clinicians.
Atrial fibrillation is a common sustained cardiac arrhythmia affecting over 30 million people worldwide, according to some estimates. Atrial fibrillation is the irregular, chaotic beating of the upper chambers of the heart. Electrical impulses discharge so rapidly that the atrial muscle quivers or fibrillates. Episodes of atrial fibrillation may last a few minutes or several days. The most serious consequence of atrial fibrillation is ischemic stroke. It has been estimated that up to 20% of all strokes are related to atrial fibrillation. Most atrial fibrillation patients, regardless of the severity of their symptoms or frequency of episodes, require treatment to reduce the risk of stroke. The left atrial appendage is a small organ attached to the left atrium of the heart as a pouch-like extension. In patients suffering from atrial fibrillation, the left atrial appendage may not properly contract with the left atrium, causing stagnant blood to pool within its interior, which can lead to the undesirable formation of thrombi within the left atrial appendage. Thrombi forming in the left atrial appendage may break loose from this area and enter the blood stream. Thrombi that migrate through the blood vessels may eventually plug a smaller vessel downstream and thereby contribute to stroke or heart attack. Clinical studies have shown that the majority of blood clots in patients with atrial fibrillation are found in the left atrial appendage. As a treatment, medical devices have been developed which are positioned in the left atrial appendage and deployed to close off the ostium of the left atrial appendage. Over time, the exposed surface(s) spanning the ostium of the left atrial appendage becomes covered with tissue (a process called endothelization), effectively removing the left atrial appendage from the circulatory system and reducing or eliminating the number of thrombi which may enter the blood stream from the left atrial appendage.
The disclosure relates to medical implants for occluding the left atrial appendage. Of the known medical devices, systems, and methods, each has certain advantages and disadvantages. There is an ongoing need to provide alternative medical devices and systems, as well as alternative methods for manufacturing and using medical devices and systems.
In one example, a medical implant for occluding a left atrial appendage may comprise an expandable framework configured to shift between a collapsed configuration and an expanded configuration. The expandable framework may include a plurality of interconnected struts and a plurality of anchor members extending radially outward from the plurality of interconnected struts in the expanded configuration. Each anchor member of the plurality of anchor members may include a base portion fixedly attached to the plurality of interconnected struts and an anchor tip portion. The anchor tip portion may include a central penetrating element and at least one tissue support element extending outward from the central penetrating element. The at least one tissue support element may be configured to be non-penetrating.
In addition or alternatively to any example described herein, the at least one tissue support element is disposed symmetrically about a central axis of the central penetrating element.
In addition or alternatively to any example described herein, the at least one tissue support element extends circumferentially about the central axis of the central penetrating element.
In addition or alternatively to any example described herein, the at least one tissue support element is configured to shift radially outward from the central penetrating element as the at least one tissue support element engages tissue.
In addition or alternatively to any example described herein, the at least one tissue support element includes a hollow interior space.
In addition or alternatively to any example described herein, the anchor tip portion extends in a first direction from a curved portion of each anchor member, the curved portion extending from the base portion to the anchor tip portion.
In addition or alternatively to any example described herein, the central penetrating element extends in the first direction to a free end.
In addition or alternatively to any example described herein, the at least one tissue support element extends outward and in the first direction from an intersection of the at least one tissue support element and the central penetrating element.
In addition or alternatively to any example described herein, the at least one tissue support element is concave, and the central penetrating element extends in the first direction from inside the at least one tissue support element.
In addition or alternatively to any example described herein, the at least one tissue support element is monolithically formed with the central penetrating element.
In addition or alternatively to any example described herein, the central penetrating element has a generally conical shape.
In addition or alternatively to any example described herein, a medical device system may comprise a catheter, a core wire movably disposed within a lumen of the catheter, and a medical implant for occluding a left atrial appendage releasably connected to a distal portion of the core wire. The medical implant may include an expandable framework configured to shift between a collapsed configuration and an expanded configuration. The expandable framework may include a plurality of interconnected struts and a plurality of anchor members extending radially outward from the plurality of interconnected struts in the expanded configuration. Each anchor member of the plurality of anchor members may include a base portion fixedly attached to the plurality of interconnected struts and an anchor tip portion. The anchor tip portion may include a central penetrating element and at least one tissue support element extending outward from the central penetrating element. The at least one tissue support element may be configured to be non-penetrating.
In addition or alternatively to any example described herein, the medical implant includes an occlusive element secured to the expandable framework.
In addition or alternatively to any example described herein, the at least one tissue support element is configured to prevent the central penetrating element from penetrating completely through a wall of the left atrial appendage.
In addition or alternatively to any example described herein, a medical implant for occluding a left atrial appendage may comprise an expandable framework configured to shift between a collapsed configuration and an expanded configuration. The expandable framework may include a plurality of interconnected struts and a plurality of anchor members extending radially outward from the plurality of interconnected struts in the expanded configuration. Each anchor member of the plurality of anchor members may include a base portion fixedly attached to the plurality of interconnected struts, an anchor tip portion, and a curved portion extending radially outward from the base portion to the anchor tip portion when the expandable framework is in the expanded configuration. The anchor tip portion may include a central penetrating element configured to penetrate into a wall of the left atrial appendage and at least one tissue support element configured to engage the wall of the left atrial appendage, the at least one tissue support element extending radially outward from the central penetrating element. The anchor tip portion may be devoid of any element configured to penetrate into the wall of the left atrial appendage other than the central penetrating element.
In addition or alternatively to any example described herein, the at least one tissue support element extends circumferentially around the central penetrating element.
In addition or alternatively to any example described herein, the at least one tissue support element is symmetric about the central penetrating element.
In addition or alternatively to any example described herein, the at least one tissue support element includes a concave portion opening toward a free end of the central penetrating element.
In addition or alternatively to any example described herein, the at least one tissue support element includes a plurality of notches formed around a perimeter of the concave portion.
In addition or alternatively to any example described herein, each notch of the plurality of notches opens toward the free end of the central penetrating element.
The above summary of some embodiments, aspects, and/or examples is not intended to describe each disclosed embodiment or every implementation of the present disclosure. The figures and detailed description which follow more particularly exemplify these embodiments.
The disclosure may be more completely understood in consideration of the following detailed description in connection with the accompanying drawings, in which:
While aspects of the disclosure are amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit aspects of the disclosure to the particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the disclosure.
The following description should be read with reference to the drawings, which are not necessarily to scale, wherein like reference numerals indicate like elements throughout the several views. The detailed description and drawings are intended to illustrate but not limit the disclosure. Those skilled in the art will recognize that the various elements described and/or shown may be arranged in various combinations and configurations without departing from the scope of the disclosure. The detailed description and drawings illustrate exemplary aspects of the disclosure.
For the following defined terms, these definitions shall be applied, unless a different definition is given in the claims or elsewhere in this specification.
All numeric values are herein assumed to be modified by the term “about,” whether or not explicitly indicated. The term “about”, in the context of numeric values, generally refers to a range of numbers that one of skill in the art would consider equivalent to the recited value (e.g., having the same function or result). In many instances, the term “about” may include numbers that are rounded to the nearest significant figure. Other uses of the term “about” (e.g., in a context other than numeric values) may be assumed to have their ordinary and customary definition(s), as understood from and consistent with the context of the specification, unless otherwise specified.
The recitation of numerical ranges by endpoints includes all numbers within that range, including the endpoints (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5).
Although some suitable dimensions, ranges, and/or values pertaining to various components, features and/or specifications are disclosed, one of skill in the art, incited by the present disclosure, would understand desired dimensions, ranges, and/or values may deviate from those expressly disclosed.
As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the content clearly dictates otherwise. As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise. It is to be noted that in order to facilitate understanding, certain features of the disclosure may be described in the singular, even though those features may be plural or recurring within the disclosed embodiment(s). Each instance of the features may include and/or be encompassed by the singular disclosure(s), unless expressly stated to the contrary. It shall be understood that the discussion(s) herein may apply equally to any and/or all of the components for which there are more than one, unless explicitly stated to the contrary.
Relative terms such as “proximal”, “distal”, “advance”, “retract”, variants thereof, and the like, may be generally considered with respect to the positioning, direction, and/or operation of various elements relative to a user/operator/manipulator of the device, wherein “proximal” and “retract” indicate or refer to closer to or toward the user and “distal” and “advance” indicate or refer to farther from or away from the user. In some instances, the terms “proximal” and “distal” may be arbitrarily assigned in an effort to facilitate understanding of the disclosure, and such instances will be readily apparent to the skilled artisan. Other relative terms, such as “upstream”, “downstream”, “inflow”, and “outflow” refer to a direction of fluid flow within a lumen, such as a body lumen, a blood vessel, or within a device. Still other relative terms, such as “axial”, “circumferential”, “longitudinal”, “lateral”, “radial”, etc. and/or variants thereof generally refer to direction and/or orientation relative to a central longitudinal axis of the disclosed structure or device.
The term “extent” may be understood to mean the greatest measurement of a stated or identified dimension, unless the extent or dimension in question is preceded by or identified as a “minimum”, which may be understood to mean the smallest measurement of the stated or identified dimension. For example, “outer extent” may be understood to mean the maximum outer dimension, “radial extent” may be understood to mean the maximum radial dimension, “longitudinal extent” may be understood to mean the maximum longitudinal dimension, etc. Each instance of an “extent” may be different (e.g., axial, longitudinal, lateral, radial, circumferential, etc.) and will be apparent to the skilled person from the context of the individual usage. In some instances, an “extent” may be measured orthogonally within a plane and/or cross-section, but may be, as will be apparent from the particular context, measured differently—such as, but not limited to, angularly, radially, circumferentially (e.g., along an arc), etc.
The terms “monolithic” and “unitary” shall generally refer to an element or elements made from or consisting of a single structure or base unit/element. A monolithic and/or unitary element shall exclude structure and/or features made by assembling or otherwise joining multiple discrete structures or elements together.
It is noted that references in the specification to “an embodiment”, “some embodiments”, “other embodiments”, etc., indicate that the embodiment(s) described may include a particular feature, structure, or characteristic, but every embodiment may not necessarily include the particular feature, structure, or characteristic. Moreover, such phrases are not necessarily referring to the same embodiment. Further, when a particular feature, structure, or characteristic is described in connection with an embodiment, it would be within the knowledge of one skilled in the art to use the particular feature, structure, or characteristic in connection with other embodiments, whether or not explicitly described, unless clearly stated to the contrary. That is, the various individual elements described below, even if not explicitly shown in a particular combination, are nevertheless contemplated as being combinable or arrangeable with each other to form other additional embodiments or to complement and/or enrich the described embodiment(s), as would be understood by one of ordinary skill in the art.
For the purpose of clarity, certain identifying numerical nomenclature (e.g., first, second, third, fourth, etc.) may be used throughout the description and/or claims to name and/or differentiate between various described and/or claimed features. It is to be understood that the numerical nomenclature is not intended to be limiting and is exemplary only. In some embodiments, alterations of and deviations from previously used numerical nomenclature may be made in the interest of brevity and clarity. That is, a feature identified as a “first” element may later be referred to as a “second” element, a “third” element, etc. or may be omitted entirely, and/or a different feature may be referred to as the “first” element. The meaning and/or designation in each instance will be apparent to the skilled practitioner.
The figures illustrate selected components and/or arrangements of medical implants, systems, and methods of manufacturing the same. It should be noted that in any given figure, some features of the medical implants, systems, and methods may not be shown, or may be shown schematically, for simplicity. Additional details regarding some elements may be illustrated in other figures in greater detail. The devices and/or methods disclosed herein may provide a number of desirable features and benefits as described in more detail below.
The medical device system 10 may include a catheter 40 having a lumen 42 extending from a proximal opening to a distal opening, a core wire 30 movably and/or slidably disposed within the lumen 42, and a medical implant 100 (e.g., a cardiovascular medical implant, an occlusive medical implant, etc.). The medical implant 100 may be configured to occlude the left atrial appendage of the patient.
The medical implant 100 may include an expandable framework configured to shift between a collapsed configuration (e.g.,
The medical implant 100 may be disposed at and/or releasably connected to a distal portion of the core wire 30. In some embodiments, the medical implant 100 may be releasably connected to the distal end of the core wire 30. The core wire 30 may be slidably and/or rotatably disposed within the lumen 42 of the catheter 40. In some embodiments, a proximal end of the core wire 30 may extend proximally of a proximal end of the catheter 40 and/or the proximal opening of the lumen 42 for manual manipulation by a clinician or practitioner.
Some suitable, but non-limiting, examples of materials for the medical device system 10, the core wire 30, the catheter 40, and/or the medical implant 100, etc. are discussed below. It is contemplated that any and/or all medical implants disclosed herein may be used in accordance with and/or be associated with the medical device system 10 described above.
The expandable framework 110 may have a longitudinal axis extending through the proximal hub 112. In some embodiments, the longitudinal axis may extend from the proximal hub 112 to the distal hub. The proximal hub 112 of the expandable framework 110 may be configured to releasably attach or connect to the distal end of the core wire 30. The proximal hub 112 of the expandable framework 110 may include a threaded insert fixedly attached to the expandable framework 110, the threaded insert being configured to engage a threaded member disposed at the distal end of the core wire 30 of the medical device system 10 to releasably connect the medical implant 100 to the distal end of the core wire 30. The expandable framework 110 may be disposed in the collapsed configuration when the medical implant 100 is disposed within the lumen 42 of the catheter 40 of the medical device system 10. The expandable framework 110 may be configured to shift toward the expanded configuration when the medical implant 100 is disposed outside of the lumen 42 of the catheter 40 of the medical device system 10 and/or when the medical implant 100 and/or the expandable framework 110 is unconstrained by the catheter 40.
In some embodiments, the medical implant 100 may include an occlusive element 120 disposed on and/or secured to the expandable framework 110 and/or the plurality of interconnected struts. In some embodiments, the occlusive element 120 may include a membrane, a mesh, a porous fabric, or other material configured to promote occlusion of the left atrial appendage and/or configured to promote endothelial ingrowth. In some embodiments, the occlusive element 120 may be disposed on, along, and/or over an exterior surface of the expandable framework 110. In some embodiments, the occlusive element 120 may cover at least 20% of the expandable framework 110 in the second configuration. In some embodiments, the occlusive element 120 may cover at least 30% of the expandable framework 110 in the second configuration. In some embodiments, the occlusive element 120 may cover at least 40% of the expandable framework 110 in the second configuration. In some embodiments, the occlusive element 120 may cover at least 50% of the expandable framework 110 in the second configuration. In some embodiments, the occlusive element 120 may cover at least 60% of the expandable framework 110 in the second configuration. In some embodiments, the occlusive element 120 may cover at least 70% of the expandable framework 110 in the second configuration. Other configurations are also contemplated.
In some embodiments, the expandable framework 110 may include a plurality of anchor members 130 extending radially outward from the plurality of interconnected struts in the expanded configuration. In some embodiments, at least some of the plurality of anchor members 130 extend through the occlusive element 120. Some additional details of the plurality of anchor members 130 are shown in
As also shown in
In some embodiments, the anchor tip portion 140 of the plurality of anchor members 130 may include a central penetrating element 142, at least one tissue support element 150 extending outward from the central penetrating element 142, and a shaft portion 160 extending opposite the central penetrating element 142, as seen in
In some embodiments, the central penetrating element 142 may be configured to penetrate into tissue and/or the wall of the left atrial appendage. The at least one tissue support element 150 may be configured to engage tissue and/or the wall of the left atrial appendage. In at least some embodiments, the at least one tissue support element 150 may extend radially outward from the central penetrating element 142. In some embodiments, the at least one tissue support element 150 may be disposed symmetrically about a central axis of the central penetrating element 142. In some embodiments, the at least one tissue support element 150 may extend circumferentially about the central axis of the central penetrating element 142. In some embodiments, the at least one tissue support element 150 may extend circumferentially around the central penetrating element 142. In some embodiments, the at least one tissue support element 150 may be symmetric about the central penetrating element 142.
In some embodiments, the anchor tip portion 140 may be devoid of any element or structure configured to penetrate into tissue and/or the wall of the left atrial appendage other than the central penetrating element 142. For example, all other structure, elements, and/or features of the anchor tip portion 140 may be expressly designed, adapted, and/or configured to avoid penetrating into tissue and/or the wall of the left atrial appendage. In at least some embodiments, the at least one tissue support element 150 may be configured to prevent the central penetrating element 142 from penetrating completely through the wall of the left atrial appendage.
In some embodiments, the anchor tip portion 140 may extend in a first direction from the curved portion 134. In some embodiments, the central penetrating element 142 extends in the first direction along the central axis from a root 144 to a free end 146. In at least some embodiments, the central penetrating element 142 has a first radial extent from the central axis at the root 144 and a second radial extent from the central axis at the free end 146, wherein the first radial extent is greater than the second radial extent. In some embodiments, the central penetrating element 142 has a generally conical shape. Other configurations, including combinations thereof, are also contemplated.
In some embodiments, the at least one tissue support element 150 may be integrally formed with the central penetrating element 142. In some embodiments, the at least one tissue support element 150 may be monolithically formed with the central penetrating element 142. In some embodiments, the at least one tissue support element 150 may be integrally formed with the central penetrating element 142 as a single monolithic structure. In some alternative configurations, the at least one tissue support element 150 and the central penetrating element 142 may be formed independently and/or separately from each and later assembled together to form the anchor tip portion 140. Other configurations, including combinations thereof, are al so contemplated.
In some embodiments, the anchor tip portion 140, the central penetrating element 142, and/or the at least one tissue support element 150 may be laser cut from a tubular structure. In some embodiments, the anchor tip portion 140, the central penetrating element 142, and/or the at least one tissue support element 150 may be laser cut from the same tubular structure as the expandable framework 110 and/or the plurality of interconnected struts. In some embodiments, the anchor tip portion 140, the central penetrating element 142, and/or the at least one tissue support element 150 may be formed from a wire, a rod, or other round stock. In some embodiments, the anchor tip portion 140, the central penetrating element 142, and/or the at least one tissue support element 150 may be machined, turned on a lathe, cut with a waterjet, formed by chemical dissolution, formed using electro discharge machining (EDM), injection molded, cast, or other suitable manufacturing means. Other configurations, including combinations thereof, are also contemplated.
In some embodiments, the anchor tip portion 140, the central penetrating element 142, and/or the at least one tissue support element 150 may have a generally polygonal cross-section (e.g., square, rectangular, hexagonal, etc.). In some embodiments, the anchor tip portion 140, the central penetrating element 142, and/or the at least one tissue support element 150 may have a generally round and/or circular cross-section. Other configurations, including combinations thereof, are also contemplated.
In some embodiments, the at least one tissue support element 150 may have different configurations. In some embodiments, the at least one tissue support element 150 may include a substantially planar surface 151 extending outward from the central penetrating element 142, as seen in
In some embodiments, the at least one tissue support element 150 may extend outward and in the first direction from an intersection of the at least one tissue support element 150 and the central penetrating element 142, as seen in
In some embodiments, the plurality of notches 154 and/or the plurality of ridges 156 may be configured to engage tissue and/or the wall of the left atrial appendage. In some embodiments, the plurality of notches 154 and/or the plurality of ridges 156 may improve stability of the anchor tip portion 140 when engaged with tissue and/or the wall of the left atrial appendage. In some embodiments, the plurality of notches 154 and/or the plurality of ridges 156 may create and/or may be configured to create mild inflammation of the tissue and/or the wall of the left atrial appendage to promote better tissue growth around the anchor tip portion 140, thereby further improving anchoring of the medical implant 100 within the left atrial appendage.
In some embodiments, the at least one tissue support element 150 may include two tissue support elements, as seen in
In some embodiments, the at least one tissue support element 150 may include four tissue support elements, as seen in
In some embodiments, the at least one tissue support element 150 may include an annular ring 170 extending circumferentially around the central axis and/or the central penetrating element 142, as seen in
In some embodiments, the at least one tissue support element 150 may be and/or include an open-ended loop 180, as seen in
In some embodiments, the at least one tissue support element 150 may be spaced apart circumferentially around the central axis of the central penetrating element 142 and/or may be spaced apart circumferentially around the central penetrating element 142. In some embodiments, the at least one tissue support element 150 may be equally spaced apart circumferentially around the central axis of the central penetrating element 142 and/or may be equally spaced apart circumferentially around the central penetrating element 142.
In some embodiments, the open-ended loop 180 may extend continuously around the central axis of the central penetrating element 142 and/or may extend continuously around the circumference of the central penetrating element 142 (e.g., similar to
In some embodiments, the at least one tissue support element 150 may be configured to shift radially outward from the central penetrating element 142 as the at least one tissue support element 150 engages the tissue 50 and/or the wall of the left atrial appendage, as shown schematically in
In some embodiments, the anchor tip portion 140 may include a proximal cavity 190 formed within the shaft portion 160 of the anchor tip portion 140. In some embodiments, the proximal cavity 190 may be sized, shaped, configured, and/or adapted to receive at least a portion of one of the plurality of anchor members 130 (e.g., the curved portion 134, an extension of the curved portion 134, etc.). In some embodiments, the proximal cavity 190 may be configured to engage with the curved portion 134 of the plurality of anchor members 130 and/or an extension of the curved portion 134, as seen in
In some alternative embodiments, the plurality of anchor members 130 and/or the anchor tip portion 140 thereof may be formed and/or assembled separately from the medical implant 100 and/or the expandable framework 110, and later fixedly attached thereto.
Referring back briefly to
In some embodiments, a method of manufacturing the medical implant 100 may include forming and/or cutting the expandable framework 110 from a unitary tubular member in the collapsed configuration. Alternatively, the method of manufacturing the medical implant 100 may include forming and/or cutting the expandable framework 110 from a flat sheet of material that is later rolled and/or formed into a tubular member. After forming the flat sheet of material into a tubular member, the tubular member may be welded or otherwise fixedly secured into a tubular shape. In some embodiments, forming and/or cutting the expandable framework 110 may be done via laser, waterjet, machining, etc. Other manufacturing methods and/or processes are also contemplated.
After forming and/or cutting the expandable framework 110, the method may include forming the expandable framework 110 into the expanded configuration. As part of forming the expandable framework 110 into the expanded configuration, the method may include bending each anchor member of the plurality of anchor members 130. In some embodiments, each anchor member may be bent individually. In some embodiments, two or more anchor members may be bent together as a group. In some embodiments, after forming the expandable framework 110 into the expanded configuration, the method may include heat setting the expandable framework 110 and/or the plurality of anchor members 130 in the expanded configuration. Other configurations and/or orders of operations are also contemplated.
In some embodiments, the method of manufacturing the medical implant 100 may include securing the occlusive element 120 to the expandable framework 110. In some embodiments, at least some of the plurality of anchor members 130 may extend through the occlusive element 120 in the expanded configuration. In some embodiments, the occlusive element 120 may be disposed on, along, and/or over an exterior surface of the expandable framework 110. Other configurations are also contemplated.
In some embodiments, the method of manufacturing the medical implant 100 may include fixedly attaching the anchor tip portion 140 to the plurality of anchor members 130, as discussed herein. In some embodiments, forming and/or cutting the expandable framework 110 may include forming and/or cutting the plurality of anchor members 130 and/or the anchor tip portion 140 thereof. Other configurations are also contemplated.
The materials that can be used for the various components of the medical implants, systems, and methods of manufacturing disclosed herein may include those commonly associated with medical devices. For simplicity purposes, the following discussion refers to the system. However, this is not intended to limit the system, devices, and/or methods described herein, as the discussion may be applied to other elements, members, components, or devices disclosed herein, such as, but not limited to, the expandable framework, the plurality of interconnected struts, the plurality of anchor members, the occlusive element, etc. and/or elements or components thereof.
In some embodiments, the system and/or components thereof may be made from a metal, metal alloy, polymer (some examples of which are disclosed below), a metal-polymer composite, ceramics, combinations thereof, and the like, or other suitable material.
Some examples of suitable polymers may include polytetrafluoroethylene (PTFE), ethylene tetrafluoroethylene (ETFE), fluorinated ethylene propylene (FEP), polyoxymethylene (POM, for example, DELRIN®), polyether block ester, polyurethane, polypropylene (PP), polyvinylchloride (PVC), polyether-ester (for example, ARNITEL®), ether or ester based copolymers (for example, butylene/poly(alkylene ether) phthalate and/or other polyester elastomers such as HYTREL®), polyamide (for example, DURETHAN® or CRISTAMID®), elastomeric polyamides, block polyamide/ethers, polyether block amide (PEBA, for example available under the trade name PEBAX®), ethylene vinyl acetate copolymers (EVA), silicones, polyethylene (PE), MARLEX® high-density polyethylene, MARLEX® low-density polyethylene, linear low density polyethylene (for example REXELL®), polyester, polybutylene terephthalate (PBT), polyethylene terephthalate (PET), polytrimethylene terephthalate, polyethylene naphthalate (PEN), polyetheretherketone (PEEK), polyimide (PI), polyetherimide (PEI), polyphenylene sulfide (PPS), polyphenylene oxide (PPO), poly paraphenylene terephthalamide (for example, KEVLAR®), polysulfone, nylon, nylon-12 (such as GRILAMID®), perfluoro(propyl vinyl ether) (PFA), ethylene vinyl alcohol, polyolefin, polystyrene, epoxy, polyvinylidene chloride (PVdC), poly(styrene-b-isobutylene-b-styrene) (for example, SIBS and/or SIBS 50A), polycarbonates, polyurethane silicone copolymers (for example, Elast-Eon® or ChronoSil®), biocompatible polymers, other suitable materials, or mixtures, combinations, copolymers thereof, polymer/metal composites, and the like. In some embodiments, the system and/or components thereof can be blended with a liquid crystal polymer (LCP). For example, the mixture can contain up to about 6 percent LCP.
Some examples of suitable metals and metal alloys include stainless steel, such as 304V, 304L, and 316LV stainless steel; mild steel; nickel-titanium alloy such as linear-elastic and/or super-elastic nitinol; other nickel alloys such as nickel-chromium-molybdenum alloys (e.g., UNS: N06625 such as INCONEL® 625, UNS: N06022 such as HASTELLOY® C-22®, UNS: N10276 such as HASTELLOY® C276®, other HASTELLOY® alloys, and the like), nickel-copper alloys (e.g., UNS: N04400 such as MONEL® 400, NICKELVAC® 400, NICORROS® 400, and the like), nickel-cobalt-chromium-molybdenum alloys (e.g., UNS: R30035 such as MP35-N® and the like), nickel-molybdenum alloys (e.g., UNS: N10665 such as HASTELLOY® ALLOY B2®), other nickel-chromium alloys, other nickel-molybdenum alloys, other nickel-cobalt alloys, other nickel-iron alloys, other nickel-copper alloys, other nickel-tungsten or tungsten alloys, and the like; cobalt-chromium alloys; cobalt-chromium-molybdenum alloys (e.g., UNS: R30003 such as ELGILOY®, PHYNOX®, and the like); platinum enriched stainless steel; titanium; platinum; palladium; gold; combinations thereof; or any other suitable material.
In some embodiments, portions or all of the system and/or components thereof may be doped with, made of, or otherwise include a radiopaque material. Radiopaque materials are understood to be materials capable of producing a relatively bright image on a fluoroscopy screen or another imaging technique (e.g., ultrasound, etc.) during a medical procedure. This relatively bright image aids a user in determining the location of the system. Some examples of radiopaque materials can include, but are not limited to, gold, platinum, palladium, tantalum, tungsten alloy, polymer material loaded with a radiopaque filler, and the like. Additionally, other radiopaque marker bands and/or coils may also be incorporated into the design of the system to achieve the same result.
In some embodiments, a degree of Magnetic Resonance Imaging (MM) compatibility is imparted into the system. For example, the system and/or components or portions thereof may be made of a material that does not substantially distort the image and create substantial artifacts (e.g., gaps in the image). Certain ferromagnetic materials, for example, may not be suitable because they may create artifacts in an MRI image. The system or portions thereof may also be made from a material that the MRI machine can image. Some materials that exhibit these characteristics include, for example, tungsten, cobalt-chromium-molybdenum alloys (e.g., UNS: R44003 such as ELGILOY®, PHYNOX®, and the like), nickel-cobalt-chromium-molybdenum alloys (e.g., UNS: R44035 such as MP35-N® and the like), nitinol, and the like, and others.
In some embodiments, the system may include a textile material. Some examples of suitable textile materials may include synthetic yarns that may be flat, shaped, twisted, textured, pre-shrunk or un-shrunk. Synthetic biocompatible yarns suitable for use in the present invention include, but are not limited to, polyesters, including polyethylene terephthalate (PET) polyesters, polypropylenes, polyethylenes, polyurethanes, polyolefins, polyvinyls, polymethylacetates, polyamides, naphthalene dicarboxylene derivatives, natural silk, and polytetrafluoroethylenes. Moreover, at least one of the synthetic yarns may be a metallic yarn or a glass or ceramic yarn or fiber. Useful metallic yarns include those yarns made from or containing stainless steel, platinum, gold, titanium, tantalum or a Ni—Co—Cr-based alloy. The yarns may further include carbon, glass or ceramic fibers. In some embodiments, the yarns may be made from thermoplastic materials including, but not limited to, polyesters, polypropylenes, polyethylenes, polyurethanes, polynaphthalenes, polytetrafluoroethylenes, and the like. The yarns may be of the multifilament, monofilament, or spun types. The type and denier of the yarn chosen may be selected in a manner which forms a biocompatible system.
In some embodiments, the system and/or other elements disclosed herein may include and/or be treated with a suitable therapeutic agent. Some examples of suitable therapeutic agents may include anti-thrombogenic agents (such as heparin, heparin derivatives, urokinase, and PPack (dextrophenylalanine proline arginine chloromethyl ketone)); anti-protein and/or anti-bacterial agents (such as 2-methacryroyloxyethyl phosphorylcholine (MPC) and its polymers or copolymers); anti-proliferative agents (such as enoxaparin, angiopeptin, monoclonal antibodies capable of blocking smooth muscle cell proliferation, hirudin, and acetylsalicylic acid); anti-inflammatory agents (such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine, and mesalamine); antineoplastic/antiproliferative/anti-mitotic agents (such as paclitaxel, 5-fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin and thymidine kinase inhibitors); anesthetic agents (such as lidocaine, bupivacaine, and ropivacaine); anti-coagulants (such as D-Phe-Pro-Arg chloromethyl ketone, an RGD peptide-containing compound, heparin, anti-thrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors, and tick antiplatelet peptides); vascular cell growth promoters (such as growth factor inhibitors, growth factor receptor antagonists, transcriptional activators, and translational promoters); vascular cell growth inhibitors (such as growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin, bifunctional molecules consisting of an antibody and a cytotoxin); immunosuppressants (such as the “olimus” family of drugs, rapamycin analogues, macrolide antibiotics, biolimus, everolimus, zotarolimus, temsirolimus, picrolimus, novolimus, myolimus, tacrolimus, sirolimus, pimecrolimus, etc.); cholesterol-lowering agents; vasodilating agents; and agents which interfere with endogenous vasoactive mechanisms.
It should be understood that this disclosure is, in many respects, only illustrative. Changes may be made in details, particularly in matters of shape, size, and arrangement of steps without exceeding the scope of the disclosure. This may include, to the extent that it is appropriate, the use of any of the features of one example embodiment being used in other embodiments. The disclosure's scope is, of course, defined in the language in which the appended claims are expressed.
This application claims the benefit of priority of U.S. Provisional Application No. 63/405,660 filed Sep. 12, 2022, the entire disclosure of which is hereby incorporated by reference.
Number | Date | Country | |
---|---|---|---|
63405660 | Sep 2022 | US |